Mitochondrial quality control: A promising target of traditional Chinese medicine in the treatment of cardiovascular disease

IF 9.1 2区医学 Q1 PHARMACOLOGY & PHARMACY

Pharmacological research Pub Date : 2025-03-26 DOI:10.1016/j.phrs.2025.107712

Deng Pan , Pengfei Chen , He Zhang , Qian Zhao , Wei Fang , Siyan Ji , Tielong Chen

{"title":"Mitochondrial quality control: A promising target of traditional Chinese medicine in the treatment of cardiovascular disease","authors":"Deng Pan , Pengfei Chen , He Zhang , Qian Zhao , Wei Fang , Siyan Ji , Tielong Chen","doi":"10.1016/j.phrs.2025.107712","DOIUrl":null,"url":null,"abstract":"<div><div>Cardiovascular disease remains the leading cause of death globally, and drugs for new targets are urgently needed. Mitochondria are the primary sources of cellular energy, play crucial roles in regulating cellular homeostasis, and are tightly associated with pathological processes in cardiovascular disease. In response to physiological signals and external stimuli in cardiovascular disease, mitochondrial quality control, which mainly includes mitophagy, mitochondrial dynamics, and mitochondrial biogenesis, is initiated to meet cellular requirements and maintain cellular homeostasis. Traditional Chinese Medicine (TCM) has been shown to have pharmacological effects on alleviating cardiac injury in various cardiovascular diseases, including myocardial ischemia/reperfusion, myocardial infarction, and heart failure, by regulating mitochondrial quality control. Recently, several molecular mechanisms of TCM in the treatment of cardiovascular disease have been elucidated. However, mitochondrial quality control by TCM for treating cardiovascular disease has not been investigated. In this review, we aim to decipher the pharmacological effects and molecular mechanisms of TCM in regulating mitochondrial quality in various cardiovascular diseases. We also present our perspectives regarding future research in this field.</div></div>","PeriodicalId":19918,"journal":{"name":"Pharmacological research","volume":"215 ","pages":"Article 107712"},"PeriodicalIF":9.1000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043661825001379","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Cardiovascular disease remains the leading cause of death globally, and drugs for new targets are urgently needed. Mitochondria are the primary sources of cellular energy, play crucial roles in regulating cellular homeostasis, and are tightly associated with pathological processes in cardiovascular disease. In response to physiological signals and external stimuli in cardiovascular disease, mitochondrial quality control, which mainly includes mitophagy, mitochondrial dynamics, and mitochondrial biogenesis, is initiated to meet cellular requirements and maintain cellular homeostasis. Traditional Chinese Medicine (TCM) has been shown to have pharmacological effects on alleviating cardiac injury in various cardiovascular diseases, including myocardial ischemia/reperfusion, myocardial infarction, and heart failure, by regulating mitochondrial quality control. Recently, several molecular mechanisms of TCM in the treatment of cardiovascular disease have been elucidated. However, mitochondrial quality control by TCM for treating cardiovascular disease has not been investigated. In this review, we aim to decipher the pharmacological effects and molecular mechanisms of TCM in regulating mitochondrial quality in various cardiovascular diseases. We also present our perspectives regarding future research in this field.

查看原文本刊更多论文

线粒体质量控制：中医治疗心血管疾病的一个有前景的靶点。

心血管疾病仍然是全球死亡的主要原因，迫切需要针对新靶点的药物。线粒体是细胞能量的主要来源，在调节细胞稳态中起关键作用，并与心血管疾病的病理过程密切相关。在心血管疾病的生理信号和外界刺激下，线粒体质量控制启动，主要包括线粒体自噬、线粒体动力学和线粒体生物发生，以满足细胞需要，维持细胞内稳态。中药已被证明通过调节线粒体质量控制来减轻各种心血管疾病（包括心肌缺血/再灌注、心肌梗死和心力衰竭）的心脏损伤。近年来，中医药治疗心血管疾病的分子机制已被阐明。然而，中医药治疗心血管疾病的线粒体质量控制尚未得到研究。在本文中，我们旨在揭示中药在各种心血管疾病中调节线粒体质量的药理作用和分子机制。本文还对该领域的未来研究提出了展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacological research 医学-药学

CiteScore

18.70

自引率

3.20%

发文量

491

审稿时长

8 days

期刊介绍： Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.